A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis

By Bannwarth Bernard   Kostine Marie   Poursac Nicolas  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 6, 2013-06 ,pp. : 753-761

Informa Healthcare

Access to resources Recommend Favorite

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis

By  

Clinical Pharmacology In Drug Development, Vol. 3, Iss. 6, 2014-11 ,pp. : 456-465

John Wiley & Sons Inc

Access to resources Recommend Favorite

Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide in Rheumatoid Arthritis in Germany: I. Selected DMARDs and Patient-Related Costs

By Schädlich Peter K.  

PharmacoEconomics, Vol. 23, Iss. 4, 2005-01 ,pp. : 377-393

Adis International

Access to resources Recommend Favorite

Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 6, 2015-06 ,pp. : 362-371

John Wiley & Sons Inc

Access to resources Recommend Favorite

Local versus Systemic Anti-Tumour Necrosis Factor-α Effects of Adalimumab in Rheumatoid Arthritis: Pharmacokinetic Modelling Analysis of Interaction between a Soluble Target and a Drug

By Stepensky David  

Clinical Pharmacokinetics, Vol. 51, Iss. 7, 2012-07 ,pp. : 443-455

Adis International

Access to resources Recommend Favorite